Advances in diagnosis and treatment of Talaromyces marneffei in patients with acquired immunodeficiency syndrome

Abstract

Abstract:

In recent years, some progresses had been made in early diagnosis and antifungal therapy of Talaromyces marneffei infection in acquired immunodeficiency syndrome (AIDS). In early clinical diagnosis, double-antibody sandwich ELISA and fluoroimmunoassay were suitable for assistant diagnosis in clinical acute stage and both were regarded highly specific. However, the two methods combining did not increase sensitivity and specificity further. Galactomannan and plasma(1-3)-β-D glucan measurement also had some early diagnostic value for Talaromyces marneffei in patients with AIDS. Sensitivity of fluorescence quantitative PCR was significantly higher than Nest's PCR method in detecting Talaromyces marneffei inparaffin embedded tissue samples, but its specificity was lower. In the treatment of Talaromyces marneffei, amphotericin B was the first choice during the induction period, and its antifungal efficacy was significantly better than that of itraconazole, although the incidence of adverse effects of the former was higher. Voriconazole and posaconazole had shown good results in retrospective studies as well as in vitro tests, and the clinical application value of the two methods still needed further study.

Key words: Talaromyces marneffei, acquired immunodeficiency syndrome, opportunistic infection

CLC Number:

R519.8

ZHOU Yi-hong, LU Yan-qiu, CHEN Yao-kai. Advances in diagnosis and treatment of Talaromyces marneffei in patients with acquired immunodeficiency syndrome[J]. Chinese Journal of Mycology, 2019, 14(5): 308-312.

References

[1] Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection:an emerging disease in mainland China[J]. Mycopathologia,2013,175(1-2):57-67.
[2] Son VT, Khue PM,Strobel M.Penicilliosis and AIDS in Haiphong, Vietnam:evolution and predictive factors of death[J]. Med Mal Infect, 2014,44(11-12):495-501.
[3] Masur H, Brooks JT, Benson CA,et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America[J]. Clin Infect Dis,2014,58(9):1308-1311.
[4] Hien HT, Thanh TT, Thu NT, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma[J]. Mycoses, 2016, 59(12):773-780.
[5] Wang YF, Cai JP, Wang YD, et al. Immunoassays based on Penicillium marneffei Mp1p derived from Pichia pastoris expression system for diagnosis of penicilliosis[J]. PLoS One,2011, 6(12):e28796.
[6] Wang Y, Zeng L, Chen X, et al. A double-antigen sandwich ELISA for detecting Penicillium marneffei Mp1p-specific antibody[J]. Nan Fang Yi Ke Da Xue Xue Bao,2013,33(3):439-443.
[7] 柳丽娟,李圣聪,谢海花,等. ELISA法和荧光免疫层析法检测马尔尼菲蓝状菌抗原的应用价值[J]. 临床检验杂, 2016,34(11):831-832.
[8] 李凌华,肖赛银,何艳,等. 血清Mp1p抗原检测对艾滋病合并马尔尼菲蓝状菌病的诊断价值[J]. 中华传染病杂志, 2017,35(3):157-160.
[9] 何凯茵,冯理智,梁志伟,等. 血清半乳甘露聚糖试验在诊断艾滋病合并马尔尼菲青霉菌病中的价值探讨[J]. 广州医科大学学报,2016,44(3):16-19.
[10] 胡家光,蒋忠胜,温小凤, 等.血浆(1-3)-β-D葡聚糖检测诊断艾滋病患者合并播散性马尔尼菲青霉菌病的临床价值[J].中华医院感染学杂志,2015,(22):5128-5130,5141.
[11] 何小庆,鲁雁秋,周怡宏, 等.重庆地区56例AIDS合并播散性马尔尼菲篮状菌病患者临床特征及死亡危险因素分析[J].传染病信息,2018,31(6):521-524.
[12] 陈媛媛,刘旭辉,侯明杰, 等.58例艾滋病合并马尔尼菲青霉菌病患者临床特征分析[J].中国艾滋病性病,2018,24(1):30-32,52.
[13] Lu S, Li X, Calderone R, et al. Whole blood Nested PCR and Real-time PCR amplification of Talaromyces marneffei specific DNA for diagnosis[J]. Med Mycol,2016,54(2):162-168.
[14] Masur H, Brooks JT, Benson CA, et al. Department of Health and Human Services. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents[J]. Clin Infect Dis,2014,58(9):1308-311.
[15] Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated Talaromycosis[J]. N Engl J Med,2017,376(24):2329-2340.
[16] Liu D, Liang L, Chen J. In vitro antifungal drug susceptibilities of Penicillium marneffei from China[J]. J Infect Chemother,2013,19(4):776-778.
[17] Ouyang Y, Cai S, Liang H, et al. Administration of voriconazole in disseminated talaromyces (Penicillium) Marneffei infection:A retrospective study[J]. Mycopathologia, 2017,182(5-6):569-75.
[18] Lau SK, Lo GC, Lam CS, et al. In vitro activity of posaconazole against Talaromyces marneffei by broth microdilution and Etest methods and comparison to itraconazole, voriconazole, and anidulafungin[J]. Antimicrob Agents Chemother[J]. 2017,61(3),e01480-e04516.
[19] Lei HL, Li LH, Chen WS, et al. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong,China[J]. Eur J Clin Microbiol Infect Dis,2018,37(6):1099-1102.